UNASSIGNED: 5090 Background: Phase I trials have established the combination of pegylated liposomal @entity632 ( @entity6065 [D]) and @entity136 as a tolerable regimen for @entity1 (pts) with recurrent @entity5 . Response rates and durations to single agent therapies in recurrent @entity43 are disappointingly low enough to warrant investigation of combination therapies. METHODS: Twenty-five pts with recurrent @entity43 were enrolled in a phase II trial of D 25mg/m2 day 1 with @entity136 650mg/m2 day 1 and 8. All pts were previously treated with @entity3003 and @entity1311 , and 11 pts had received a second @entity902 regimen for @entity66 . Four pts were @entity902 refractory, four were @entity902 resistant, and 17(68%) were @entity902 sensitive with a mean of 14.5 (range 7 to 29) months since the last @entity902 therapy. The median number of prior chemotherapy regimens was 2 (range 1 to 4). All pts had measurable disease and radiographic responses were determined with CAT scans every three cycles. RESULTS: Twenty-four pts completed 3 to 12 (mean 6) cycles of therapy, and one pt was lost to followup after cycle four. Objective responses were demonstrated in 16 (64%) pts. Seven pts achieved a complete response (CR) with a mean progression free interval (PFI) of 7 (range 6 to 18) months. Nine (36%) pts had a partial response (PR) and six (24%) pts demonstrated @entity66 ( @entity66 ). The PFI for both PR and @entity66 pts was 5.4 (range 3 to 10) months. Three (12%) pts showed progression at cycle 3. Overall 22/25 (88%) pts demonstrated a clinical benefit with disease response or stabilization (17/17 @entity902 sensitive vs. 5/8 @entity902 resistant/refractory). Two pts with PR withdrew secondary to @entity137 at 4 and 5 cycles (recurrent @entity31727 ) @entity882 , @entity5515 ). There were no episodes of @entity1398 . Transient @entity31727 @entity1398 was observed in 6 (24%) pts and @entity31727 @entity882 in one. CONCLUSIONS: The combination of D and @entity136 is an active regimen for recurrent @entity43 , with response rates that exceed those reported for either single agent. No significant financial relationships to disclose.

XXXX and @entity136 combination therapy for recurrent @entity43 : Results of a phase II trial.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease', 'SD', 'relapsed disease'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity6065 :: ('MESH:C506643', 'Chemical') :: ['Doxil'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['taxol'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity31727 :: ('57827', 'Gene') :: ['grade 4 (G 4', 'G 4'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity5515 :: ('MESH:D017499', 'Disease') :: ['palmar plantar erythrodysesthesia']
@entity6065 :: (MESH:C506643,Chemical) :: ['Doxil']
